Cam L. Garner, Director.  Mr. Garner is a pharmaceutical executive with diverse experience in the healthcare industry ranging from diagnostics and devices to pharmaceuticals.  Mr. Garner was Chief Executive Officer of Dura Pharmaceuticals, Inc. from 1989-1995 and Chairman and CEO from 1995-2000. Dura was sold to Elan in November 2000, for $1.8 billion. Mr. Garner has co-founded specialty pharmaceutical companies, Verus Pharmaceuticals, Inc., Cadence Pharmaceuticals, Inc., Evoke Pharma, Zogenix, Inc., Xcel Pharmaceuticals, Inc. and DJ Pharma.  He serves as Chairman and CEO of Verus and Chairman of Cadence, Evoke Pharma and Zogenix.  Xcel Pharmaceuticals was sold in March, 2005 to Valeant International and DJ Pharma was sold to Biovail in 2000. In addition, he serves on the Board of Directors of Pharmion Corporation, Somaxon Pharmaceuticals, Favrille, Inc. and SkinMedica, Inc. Mr. Garner earned a Master's Degree in Business Administration from Baldwin-Wallace College in Berea, Ohio, and a Bachelor of Arts Degree in Biology from Virginia Wesleyan.

Edward T. Maggio, Ph.D., Chief Executive Officer and Director. Prior to co-founding Aegis, Dr. Maggio served as the Chief Executive Officer of Cengent Therapeutics Inc. He is the former President and Chief Executive Officer of ImmunoPharmaceutics, Inc. (IPI), which developed a number of endothelin antagonists, including Pfizer’s (formerly Encysive Pharmaceuticals') Thelin® (Sitaxsentan), approved in 2006 for sale in Europe for cardiovascular disease. Dr. Maggio has been a founder and board member of seven public and private life science companies in the San Diego area and one in Copenhagen, Denmark. He received his Ph.D. from the University of Michigan and was an NIH postdoctoral fellow at the University of California, San Francisco (UCSF) Department of Pharmaceutical Chemistry. He is a member of the Board of Fellows of Polytechnic University, New York; and serves on the University of California, San Diego Dean's Board of Advisors for Biological Sciences; the California State University, San Marcos, Biotechnology Programs Advisory Board; and the Industry Council of the San Diego Consortium for Regenerative Medicine. Dr. Maggio has edited and coauthored a number of books and scientific articles in the biotechnology area and is an author of more than three-dozen issued and pending U.S. and foreign patents.

Ralph R. Barry, Chief Business Officer and Director.
Prior to co-founding Aegis, from February 1998 through April 2003, Mr. Barry served as Vice President and Chief Financial Officer and Secretary of Structural Bioinformatics, Inc. (now Cengent Therapeutics, Inc.). Prior to joining the Company, Mr. Barry served as Vice President and Chief Financial Officer and Secretary of Imaging Technologies Corporation (Nasdaq: ITEC), a leader in the development of laser printer and imaging technologies. Mr. Barry joined ITEC as Controller and Chief Accounting Officer in October 1993, and became its Chief Financial Officer and Secretary in August 1995 its Vice President of Finance in December 1996. Prior to joining ITEC, Mr. Barry served in the Washington, D.C., and San Diego offices of Price Waterhouse, LLP from August 1989 through October 1993. Mr. Barry is on the Board of Management of the San Diego branch of the YMCA-Camps Division and serves as its Treasurer. Mr. Barry received a B.S. in accounting from the University of Maryland and is a non-practicing CPA.

Elaine M. Phillips, Ph.D. Dr. Phillips is a senior pharmaceutical industry executive with more than 15 years of experience in pharmaceutical product development and commercialization, including aerosol formulations, CMC, solid state characterization, and package development. She is currently Senior Vice President, Technical Operations of Verus Pharmaceuticals Inc. Prior to joining Verus, Dr. Phillips held senior management positions at Dura Pharmaceuticals and Elan Corporation and was a founding partner at  ProPharmaCon, LLC, a product development and regulatory consulting company. Dr. Phillips earned her Ph.D. in Pharmaceutics from Virginia Commonwealth University, a B.SC. in Chemical Engineering from the University of Kentucky and performed post-doctoral studies in pharmaceutical chemistry at the University of Kansas. She has published numerous research articles on the study of crystal growth, aerosol delivery, controlled release and pharmaceutical applications of super critical fluids.

Alfred G. Ferris, Director. Mr. Ferris, the senior founding principal and president of Ferris & Britton, PC, a law firm devoted to corporate and corporate securities practice, was admitted to the California Bar in 1964. He is recognized for his expertise in the corporate securities, high-technology, biotechnology, cable television and labor (management) areas of corporate practice. Mr. Ferris is a member of the California, American and San Diego Bar Associations and has served as chairman and member of several California State Bar committees and boards. He is on the National Panel of Arbitrators of the American Arbitration Association and has served as adjunct professor of law at the University of San Diego School of Law. He received his undergraduate and law degrees from Stanford University.

Jon B. Bruss, MD, MSPH, MBA, Dr. Bruss, is the president and founder of Alarus Development International, a consulting firm specializing in clinical drug development strategies. Dr. Bruss is a board certified pediatrician and specialist in infectious disease with experience in clinical pediatrics, public health management, and drug and biologics development (Phases I-IV). He has a broad understanding of the principles of scientific research and the commercialization of medicines across multiple therapeutic areas. Dr. Bruss has successfully registered drugs in the US, Europe, and Japan, including negotiations with regulatory authorities in these countries. He has experience with full pediatric development programs including complex studies in neonates. Prior to Alarus, he was Executive Vice President & Chief Medical Officer of PediaMed Pharmaceuticals, Inc., a pharmaceutical company specializing in products for children, and before that a former Clinical Program Director of infectious disease research for Pfizer/Pharmacia. Dr. Bruss received his MD from the University of New Mexico and then completed a pediatric residency at the Children's Hospital of New Mexico. He completed a fellowship in pediatric infectious diseases at Harvard Medical School and Boston Children's Hospital and remained on faculty conducting vaccine related research. He received a MSPH degree at Tulane University, School of Public Health and a MBA degree at Kellogg School of Business Management, Northwestern University. He has held academic positions at Harvard Medical School and the University of Washington.

Elias Meezan, Ph.D., Advisory Board, is a co-inventor of the Intravail® technology. Dr. Meezan is Professor of Pharmacology and Toxicology at the University of Alabama at Birmingham. He served on the faculties of Duke University and the University of Arizona before coming to UAB as Professor and Chairman of the Department of Pharmacology, a position he held for ten years. Dr. Meezan received his Ph.D. at Duke University and was a Helen Hay Whitney postdoctoral fellow at M.I.T. and the California Institute of Technology. He is the author and co-author of more than 100 scientific publications and has developed several innovative technologies including the first widely used methods for the isolation of brain and retinal microvessels and for the isolation of basement membrane and extracellular matrix which have been employed in many studies relevant to the biology of these tissue components in health and disease. His current research is focused on the biochemical pharmacology of the alkylmaltosides and their applications for the treatment of diabetes and cystic fibrosis as well as in drug delivery.

Dennis J. Pillion, Ph.D., Advisory Board, is a co-inventor of the Intravail® technology. Dr. Pillion holds his Ph.D. in Cell and Molecular Biology from the Medical College of Georgia and served as a Postdoctoral Fellow in the laboratory of Dr. Michael Czech at Brown University and is currently is a Professor in the Department of Pharmacology & Toxicology at the UAB School of Medicine. Dr. Pillion has been interested in various aspects of diabetes research and education for the past 24 years. His laboratory has investigated insulin binding and action in isolated tissues and cells. Currently, he is studying the possibility of delivering insulin and other drugs at therapeutic levels using ocular, nasal or oral formulations containing novel absorption-enhancing agents. Dr. Pillion also serves as the Course Director for the Medical Pharmacology courses offered to 161 medical students, 55 dental students and 44 optometry students each year at UAB.Dr. Pillion currently serves as the Director of Staff Education, and Past Chairman of the Board of Directors for Alabama’s Camp for Children with Diabetes. He also serves as President of the American Diabetes Association, Birmingham Leadership Council. Dr. Pillion is co-founder of the Diabetes Care Network of Alabama, a start-up company in Birmingham, Alabama involved in delivering diabetes education to employees in the workplace setting.

Stephen M. Chang, Ph.D. Dr. Chang is President of publicly traded MultiCell Technologies Inc. which specializes in innovative cell immortalization techniques leading to the reproducible creation of highly functional cell lines and therapeutic products. He is also CEO of privately held Astral Therapeutics, a San Diego biotechnology company developing novel therapies for diabetes and other autoimmune diseases and President of CURES (www.curescalifornia.org) a coalition of patient advocates, biotechnology companies, pharmaceutical companies and venture capitalists dedicated to ensuring the safety, research and development of innovative life saving medications. Dr Chang is an active board member of BIOCOM, San Diego's premier life sciences organization. Dr. Chang was chief science officer and vice president of Canji Inc./Schering Plough Research Institute in San Diego from 1998 to 2004, managing four large external biotech corporate partnerships with Transgene, Myriad Genetics, Genzyme and Immune Response. From 1995 to 1997, Dr. Chang was director of research for Chiron Viagene, and Chiron Inc., where he headed four research departments: genetic programs, viral therapeutics and delivery, cancer therapeutics and gene transfer immunology and immunobiology. He has filed more than 40 patents worldwide and is extensively published.

Alan Donald, MS, MBA, RAC, Advisory Board. Mr. Donald is president of Matrix Medical Consulting, Inc., a firm specializing in U.S. and international regulatory, clinical study and quality assurance services for developers and manufacturers of medical device, biotechnology and pharmaceutical products.  Mr. Donald has 28 years experience in the industry and has held senior management positions in a diversity of biomedical companies.  In addition, Mr. Donald is a Professor in Regulatory Affairs in the graduate school at the Center for Bio/Pharmaceutical and Biodevice Development at San Diego State University.   Mr. Donald received his undergraduate education at Claremont McKenna College, a member of the Claremont Colleges, and Harvard University, receiving a bachelor’s in biology/physiology.  Mr. Donald received a Master’s degree in biochemistry/cell biology with highest honors from San Diego State University and a Master’s in Business (MBA) from the University of California.  Additionally, Mr. Donald is certified by the Regulatory Affairs Professional Society (RAPS), an ISO Lead Auditor, co-Chairman of the BIOCOM/San Diego FDA Committee, a member of several professional societies and has numerous publications. More information on Mr. Donald and Matrix Medical Consulting, Inc. can be found at www.matrixmedcorp.com

Jack J. Florio. Mr. Florio has over 28 years of US and global experience with Eli Lilly and Company in sales, marketing, business development, and new product planning and development. He held various pharmaceutical management positions with Lilly including Team Leader – Global Late Life Cycle Products Team; Executive Director – European Marketing, and Director – Global Pharmaceutical Pricing Development. During his career at Lilly, Mr. Florio actively directed product launch activities from a variety of functional or geographic perspectives including neuroscience, gastrointestinal, anti infectives, and hospital products that have included products such as PROZAC, ZYPREXA, AXID, LORABID, among others.Since moving to San Diego several years ago, Mr. Florio has assumed interim management positions focused primarily on corporate and business development in a number of life science companies. He is on the Board of the San Diego Tech Coast Angels, ChemNavigator, and the Forum for Women Entrepreneurs. Mr. Florio received an MBA in Marketing and APC in Management from New York University and a B.S. in Pharmacy from Columbia University, College of Pharmaceutical Sciences.

John J. Nestor, Jr., Ph.D.  Dr. Nestor is the founding CEO of TheraPei Pharmaceuticals, Inc..  He has more than 25 years of pharmaceutical industry experience in drug discovery and scientific management, much of that time at the VP level in major pharma, including 8 years as Vice President, Syntex Discovery Research and Director of the Syntex Institute of Bio-Organic Chemistry. Following the acquisition of Syntex by Roche, he served as Distinguished Scientist in the Roche Bioscience organization (Roche Research Vice President level), where he worked until co-founding a chemistry-focused, drug discovery company, Helios Pharmaceuticals. He is co-inventor of 10 compounds that have reached the clinical development stage, including three that are now marketed drugs (Synarel®, Antagon®, Valcyte®). Immediately prior to founding TheraPei Pharmaceuticals, Dr. Nestor was Executive Vice President, Drug Discovery at Sequenom.